Amgen's best chance at breaking into the high-stakes obesity drug market got its start in a basement at the University of Iceland Science Park in Reykjavík, in a freezer chilled to minus-13 degrees Fahrenheit. Bloomberg's Madison Muller explains.
Source: [Bloomberg Markets](https://www.bloomberg.com/news/videos/2026-11-02/the-icelandic-dna-behind-amgen-s-hunt-for-the-next-ozempic)